Drs. Krish Patel and Gwen Nichols join SOHO Insider community oncology series
SOHO Insider is pleased to announce two new upcoming sessions in our Community Oncology Brown Bag Series, hosted by Loretta J. Nastoupil, MD.
SOHO Insider is pleased to announce two new upcoming sessions in our Community Oncology Brown Bag Series, hosted by Loretta J. Nastoupil, MD.
Daniel Zheng, MD, a pediatric oncologist at the Children's Hospital of Philadelphia, and Chiara Bona, MD, a pediatric oncologist at Dana-Farber Boston Children's
Dr. Manson covers the importance of treating the underlying driver of HLH to prevent recurrence and improve patient outcomes. She also highlights resources
The approval is based on the phase 3 BRUIN CLL-321 trial, the first randomized study in patients pre-treated with a covalent BTK inhibitor.
Iberdomide is the first in a new class of medicines called cereblon E3 ligase modulator (CELMoD) agents, which utilize targeted protein degradation to
The filing was supported by results from the phase 2 PROSPECT study, which demonstrated an overall response rate of 67 percent and a
In a phase 3 clinical trial, the combination showed significant improvements in progression-free survival and overall survival compared with the standard of care.
Results from the phase 3 VERIFY study supported the filing, showing that the drug improved hematocrit levels and lowered the frequency of required
While we cannot ignore the wider challenges facing the NHS, the SOHO UK programme highlights the extraordinary pace of progress in haematology. Alongside
The upcoming Phase 2 study will utilize a Simon 2-stage design and focus on patients who have not previously received a menin inhibitor.